Cel Strabismus, the disorder in which the eyes do not line up in the same direction, affects around 10.5 million Europeans.Around 30% of strabismus surgeries need to be repeated due to inaccurate ocular measurements. At any point in time,about 10% of the adult population will report having some type of mental or behavioral disorder, such as schizophrenia.These two seemingly unrelated pathologies have one thing in common: they can be detected using ocular biomarkers. Thegoal of this project is to validate ocular biomarkers for a range of pathologies, including ophthalmological, neurological,mental, and endocrinological disorders. The clinical validations will be conducted using GazeLab, a computer vision-basedsystem that accurately measures ocular motility and pupillary dynamics. Our innovative all-in-one solution can be deployedas a point-of-care diagnostic tool, leading to quicker and more effective treatments for a variety of disorders.Strabismus patients are the first beneficiaries of our technology and are currently driving demand for GazeLab within theophthalmological sector. As we validate more biomarkers for ocular pathologies we will add value to our product forophthalmologists. Mental health professionals overwhelmingly diagnose subjectively, and can miss physiological symptomsthat ocular biomarkers can detect.The goal of this SME Instrument phase 1 project is to determine if GazeLab represents a scalable, repeatable business model to help diagnose a variety of pathologies. If this is the case, we will proceed to request funding through phase 2. In phase 2 we aim to conduct large-scale validations necessary for GazeLab to be approved for the defined applications in a clinical setting. Our target markets include ophthalmologists, neuro-ophthalmologists, neurologists and psychiatrists. Our ultimate goal is to position GazeLab as the industry standard for precision ocular motility measurement and pupillography throughout a range of clinical specialties Dziedzina nauki medical and health sciencesclinical medicineophthalmologystrabismus Program(-y) H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being Main Programme H2020-EU.3.1.3. - Treating and managing disease Temat(-y) PHC-12-2015-1 - Clinical research for the validation of biomarkers and/or diagnostic medical devices Zaproszenie do składania wniosków H2020-SMEInst-2014-2015 Zobacz inne projekty w ramach tego zaproszenia Szczegółowe działanie H2020-SMEINST-1-2015 System finansowania SME-1 - SME instrument phase 1 Koordynator BCNINNOVA TECHNOLOGICAL EVOLUTION SL Wkład UE netto € 50 000,00 Adres CALLE COVADONGA 378 4 1 A 08203 Barcelona Hiszpania Zobacz na mapie MŚP Organizacja określiła się jako MŚP (firma z sektora małych i średnich przedsiębiorstw) w czasie podpisania umowy o grant. Tak Region Este Cataluña Barcelona Rodzaj działalności Private for-profit entities (excluding Higher or Secondary Education Establishments) Linki Kontakt z organizacją Opens in new window Uczestnictwo w unijnych programach w zakresie badań i innowacji Opens in new window sieć współpracy HORIZON Opens in new window Koszt całkowity € 71 429,00